STOCK TITAN

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated news page for Jaguar Health (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.

Rhea-AI Summary
Jaguar Health, Inc. has announced that it has successfully planted over 1.1 million trees in the Peruvian Amazon since 1992 as part of its commitment to biocultural conservation and the development of new therapeutics. The reforestation program aims to mitigate global warming and support sustainable management of the rainforest. The company's efforts have benefited an estimated 100,000 people and created incentives for conserving and utilizing the tropical forests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
none
-
Rhea-AI Summary
Jaguar Health, Inc. (JAGX) announced that two leading veterinary oncologists will serve as Principal Investigators for the company's planned clinical field study of Canalevia-CA1, the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive FDA conditional approval. Canalevia-CA1 is available from multiple leading veterinary distributors in the U.S., and the clinical field study aims to support full approval of the product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.04%
Tags
-
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX): Napo Pharmaceuticals to Participate in Educational Panel at Butt Stuff Brunch with Doctor Carlton
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.16%
Tags
none
Rhea-AI Summary
Jaguar Health, Inc. announced the voting results of its 2023 Annual Meeting of Stockholders. Five proposals were approved by the stockholders. The details of the proposals can be found in the Company's proxy statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Napo Pharmaceuticals, a subsidiary of Jaguar Health, has submitted an IND application to the FDA for a new crofelemer powder for the treatment of microvillus inclusion disease (MVID), a rare and life-threatening condition that affects newborns and children. The company plans to host a webinar with pediatric gastroenterologists to discuss the value of managing diarrhea in MVID patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
AI
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

JAGX Stock Data

24.94M
274.29M
1.78%
0.45%
8.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About JAGX

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/